Literature DB >> 11368984

Vaginal misoprostol 1000 microg for early abortion.

J L Carbonell1, J Rodriguez, S Aragón, A Velazco, R Tanda, C Sánchez, S Barambio, S Chami, F Valero.   

Abstract

The objective of this study was to evaluate the safety and efficacy of 1000 microg misoprostol vaginally (Cytotec) self-administered into the vagina for medical abortion. Three-hundred women with gestations between 42 and 63 days, with previous written consent, received vaginal misoprostol every 24 h up to a maximum of three doses for abortion. Outcome measures assessed included: successful abortion (complete abortion without surgery), side effects, decrease in hemoglobin, mean time of vaginal bleeding, mean expulsion time and mean time of returning of menses. Complete abortion occurred in 279/300 (93.0%, 95% CI 90, 96) patients. Medication to relieve symptoms was administered to all subjects after every misoprostol dose. Vaginal bleeding lasted 14.7 +/- 5.4 days. Mean expulsion time was 8.1 +/- 3.0 h for those who aborted after the first misoprostol dose. The mean drop in hemoglobin was statistically significant (p = 0.0001) but without clinical relevance. The frequencies of nausea and diarrhea were high. According to the observed outcomes, 1000-microg misoprostol vaginally could be a valid method to terminate pregnancies up to nine weeks gestation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368984     DOI: 10.1016/s0010-7824(01)00189-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review.

Authors:  Elizabeth G Raymond; Margo S Harrison; Mark A Weaver
Journal:  Obstet Gynecol       Date:  2019-01       Impact factor: 7.661

2.  The potential of medical abortion to reduce maternal mortality in Africa: what benefits for Tanzania and Ethiopia?

Authors:  Rebecca F Baggaley; Joanna Burgin; Oona M R Campbell
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.